JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: JNJ-54416076 (Oral Suspension)

First Posted Date: 2016-11-01

Last Posted Date: 2017-12-20

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT02951845

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64179375
Drug: Placebo
Drug: 4 Factor Prothrombin Complex Concentrate (PCC)

First Posted Date: 2016-10-31

Last Posted Date: 2017-09-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 80

Registration Number: NCT02949206

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-53718678

First Posted Date: 2016-10-26

Last Posted Date: 2020-03-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 82

Registration Number: NCT02945007

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate mesylate
Drug: Odalasvir (ODV)
Drug: Simeprevir (SMV)

First Posted Date: 2016-10-26

Last Posted Date: 2017-06-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 15

Registration Number: NCT02945020

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

Phase 2

Terminated

Conditions: Respiratory Syncytial Viruses

Interventions: Drug: Placebo
Drug: lumicitabine

First Posted Date: 2016-10-17

Last Posted Date: 2019-12-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 49

Registration Number: NCT02935673

A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: JNJ-54175446

First Posted Date: 2016-10-14

Last Posted Date: 2017-01-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 25

Registration Number: NCT02933762

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-56136379
Other: Placebo

First Posted Date: 2016-10-14

Last Posted Date: 2018-03-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT02933580

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-54175446 (capsule)
Drug: JNJ-54175446 (suspension)

First Posted Date: 2016-10-12

Last Posted Date: 2017-02-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT02930694

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Daratumumab

First Posted Date: 2016-10-07

Last Posted Date: 2021-01-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT02927925

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China

and more 14 locations

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Niraparib
Drug: Apalutamide
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2016-10-05

Last Posted Date: 2020-07-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 34

Registration Number: NCT02924766

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy